Last reviewed · How we verify

Dropless Regimen

University of California, San Francisco · FDA-approved active Small molecule

A perioperative anti-inflammatory regimen that eliminates the need for postoperative topical corticosteroid and nonsteroidal anti-inflammatory eye drops following cataract surgery.

A perioperative anti-inflammatory regimen that eliminates the need for postoperative topical corticosteroid and nonsteroidal anti-inflammatory eye drops following cataract surgery. Used for Postoperative inflammation and pain management following cataract surgery.

At a glance

Generic nameDropless Regimen
SponsorUniversity of California, San Francisco
Drug classAnti-inflammatory combination regimen
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

The dropless regimen uses sustained-release or long-acting anti-inflammatory agents (typically corticosteroids and NSAIDs) administered intraoperatively or perioperatively via intracameral injection, subconjunctival injection, or oral formulations to provide extended anti-inflammatory coverage without requiring patient-administered topical drops. This approach reduces inflammation, pain, and the risk of corneal complications while improving patient compliance by eliminating the need for multiple daily eye drop instillations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: